Antagonism by Ganoderma lucidum polysaccharides Against the suppression by culture supernatants of b16f10 melanoma cells on macrophage

Phytotherapy Research

Volumn 28, Issue 2, 2014, Pages 200-206

  Lu, Jie ^a   Sun, Li Xin ^a,b   Lin, Zhi Bin ^b   Duan, Xin Suo ^a   Ge, Zhi Hua ^a   Xing, En Hong ^a   Lan, Tian Fei ^a   Yang, Ning ^a   Li, Xue Jun ^b   Li, Min ^b   Li, Wei Dong ^b  

^a CHENGDE MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Ganoderma lucidum polysaccharides; immunosuppression; macrophage; phagocytosis; tumor; tumor necrosis factor

Indexed keywords

GANODERMA LUCIDUM POLYSACCHARIDES; IMMUNOSUPPRESSION; MACROPHAGE; PHAGOCYTOSIS; TUMOR; TUMOR NECROSIS FACTOR Α;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA; MACROPHAGES, PERITONEAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PHAGOCYTOSIS; POLYSACCHARIDES; REISHI; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893723699     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4980     Document Type: Article

References (51)

1. Bancroft GJ, Schreiber RD, Unanue ER,. 1991. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev 124: 5-24.
2. Blankenstein T, Qin ZH, Uberla K, et al,. 1991. Tumor suppression after tumor celltargeted tumor necrosis factor α gene transfer. J Exp Med 173: 1047-1052.
3. Boehm U, Klamp T, Groot M, Howard JC,. 1997. Cellular responses to interferon-γ. Annu Rev Immunol 15: 749-795.
4. Cao LZ, Lin ZB,. 2002. Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett 83: 163-169
5. Cao LZ, Lin ZB,. 2003. Regulatory effect of Ganoderma lucidum polysaccharides on cytotoxic T-lymphocytes induced by dendritic cells in vitro. Acta Pharmacol Sin 24: 312-326
6. Cao QZ, Lin ZB,. 2006. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci 78: 1457-1463
7. Chan WK, Cheung CC, Law HK, Lau YL, Chan GC,. 2008. Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. J Hematol Oncol 1: 9.
8. Das ND, Jung KH, Park JH, et al,. 2011. Terminalia chebula extract acts as a potential NF-κB inhibitor in human lymphoblastic T cells. Phytother Res 25: 927-934.
9. Dighe AS, Richards E, Old LJ, Schreiber RD,. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1: 447-456.
10. Dunn GP, Old LJ, Schreiber RD,. 2004a. The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.
11. Dunn GP, Old LJ, Schreiber RD,. 2004b. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
12. Elgert KD, Alleva DG, Mullins DW,. 1998. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290.
13. Fuchs EJ, Matzinger P,. 1996. Is cancer dangerous to the immune system? Semin Immunol 8: 271-280.
14. Gordon S,. Alternative activation of macrophages. 2003. Nat Rev Immunol 3: 23-35.
15. Gross S, Walden P,. 2008. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunol Lett 116: 7-14
16. Harris DP, Haynes L, Sayles PC, et al,. 2000. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1: 475-482.
17. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T,. 2001. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 194: 1549-1559.
18. Jadus MR, Irwin MC, Irwin MR, et al,. 1996. Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood 87: 5232-5241.
19. Kaplan DH, Shankaran V, Dighe AS, et al,. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561.
20. Kim R, Emi M, Tanabe K,. 2006. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119: 254-264.
21. Lamagna C, Aurrand-Lions M, Imhof BA,. 2006. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80: 705-713.
22. Lee CL, Jiang P, Sit WH, Yang X, Wan JM,. 2010. Regulatory properties of polysaccharopeptide derived from Coriolus versicolor and its combined effect with ciclosporin on the homeostasis of human lymphocytes. J Pharm Pharmacol 62: 1028-1036.
23. Lewis CE, Pollard JW,. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612
24. Li QQ, Wang G, Reed E, Huang L, Cuff CF,. 2010. Evaluation of Cisplatin in Combination with beta-Elemene as a Regimen for Prostate Cancer Chemotherapy. Basic Clin Pharmacol Toxicol 107: 868-876
25. Li WD, Zhang BD, Wei Ran, Liu JH, Lin ZB,. 2008. Reversal effect of Ganoderma lucidum polysaccharide on multidrug resistance in K562/ADM cell line. Acta Pharmacol Sin 29: 620-627
26. Lin ZB, Zhang HN,. 2004. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 25: 1387-1395.
27. Long S, Guangzhi Y, Baojie G, et al,. 2012. Shikonin Derivatives Protect Immune Organs from Damage and Promote Immune Responses In Vivo in Tumour-bearing Mice. Phytother Res 26: 26-33
28. Lõpez P, Ferraro G, Anesini C,. 2011. Comparative antioxidant activity of an extract of Lithraea molleoides and an isolated 5-alkyl resorcinol derivative. Effects on the proliferation of normal and tumoral lymphocytes. Phytother Res 25: 271-276.
29. MacMicking J, Xie QW, Nathan C,. 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350.
30. Mantovani A, Allavena P, Sica A,. 2004. Tumor-associated macrophages as a prototypic type II polarized phagocyte population: role in tumor progression. Eur J Cancer 40: 1660-1667.
31. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A,. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
32. Mantovani A,. 1994. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 71: 5-16.
33. McBride WH,. 1986. Phenotype and functions of intratumoral macrophages. Biochim Biophys Acta 865: 27-41.
34. Meng L, Zhu W, Jiang C, et al,. 2010. Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res Ther 12: R103.
35. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D,. 2004. Part I: Vaccines for solid tumours. Lancet Oncol 5: 681-689.
36. Munder M, Mallo M, Eichmann K, Modolell M,. 1998. Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 187: 2103-2108.
37. Nathan CF,. 1987. Secretory products of macrophages. J Clin Invest 79: 319-326.
38. Rosenberg SA, Yang JC, Restifo NP,. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
39. Sica A, Bronte V,. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166.
40. Sica A, Schioppa T, Mantovani A, Allavena P,. 2006. Tumorassociated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727.
41. Song Y, Yang J, Bai WL, Ji WY,. 2011. Antitumor and immunoregulatory effects of astragalus on nasopharyngeal carcinoma in vivo and in vitro. Phytother Res 25: 909-915.
42. Street SE, Cretney E, Smyth MJ,. 2001. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97: 192-197.
43. Street SE, Trapani JA, MacGregor D, Smyth MJ,. 2002. Suppression of lymphoma and epithelial malignancies effected by interferon γ. J Exp Med 196: 129-134.
44. Sun LX, Lin ZB, Li XJ, et al,. 2011a. Promoting effects of Ganoderma lucidum Polysaccharides on B16F10 cells to activate lymphocytes. Basic Clin Pharmacol Toxicol 108: 149-154.
45. Sun LX, Lin ZB, Duan XS, et al,. 2011b. Ganoderma lucidum polysaccharides antagonized the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells. J Pharm Pharmacol 63: 725-735.
46. Whiteside TL,. 2006. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15.
47. Yang L, Carbone DP,. 2004. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92: 13-27.
48. Yang X, Hu W, Zhang Q, Wang Y, Sun L,. 2010. Puerarin Inhibits C-Reactive Protein Expression via Suppression of Nuclear Factor κB Activation in Lipopolysaccharide-Induced Peripheral Blood Mononuclear Cells of Patients with Stable Angina Pectoris. Basic Clin Pharmacol Toxicol 107: 637-642.
49. Zhu XL, Chen AF, Lin ZB,. 2007. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol 111: 219-226
50. Zhu XL, Lin ZB,. 2005. Effect of Ganoderma lucidum polysaccharides on cytokine-induced killer cells proliferation and cytotoxicity. Acta Pharmacol Sin 26: 1130-1137.
51. Zou W,. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.